As medical providers, you are constantly bombarded with messages from laboratories trying to sell you products, promising their technology is second to none and guaranteeing they can take care of all your patients. But, professional experience has revealed to you that is not the case. We hear these same messages at Insight with the added benefit of an experience team of genetic professionals to evaluate the technology and determine what tests make the most sense for our patient population.
A recent committee option just issued by the American College of Obstetricians and Gynecologists endorses, for the first time, expanded carrier screening as an acceptable strategy for preconception and prenatal carrier screening.
It has been well established that while the majority of ovarian cancers arise sporadically, up to 20% are considered to be hereditary. Mutations in the BRCA1 and BRCA2 genes provide an explanation in many of these hereditary cases, but not all suggestive personal and family histories are explained by BRCA1/2. As our awareness of additional ovarian-cancer susceptibility genes continues to grow, the scope of available genetic testing has also begun to expand.
A third Committee Opinion from ACOG provides increased support for genetic counseling as part of the prenatal and hereditary cancer testing process.